2,421
Views
156
CrossRef citations to date
0
Altmetric
Research Article

Opioid receptors and legal highs: Salvia divinorum and Kratom

, &
Pages 146-152 | Received 11 Oct 2006, Accepted 22 Jan 2007, Published online: 20 Jan 2009
 

Abstract

Salvia divinorum and Mitragyna speciosa (“Kratom”), two unscheduled dietary supplements whose active agents are opioid receptor agonists, have discrete psychoactive effects that have contributed to their increasing popularity. Salvia divinorum contains the highly selective kappa- opioid receptor agonist salvinorin A; this compound produces visual hallucinations and synesthesia. Mitragynine, the major alkaloid identified from Kratom, has been reported as a partial opioid agonist producing similar effects to morphine. An interesting minor alkaloid of Kratom, 7-hydroxymitragynine, has been reported to be more potent than morphine. Both Kratom alkaloids are reported to activate supraspinal mu- and delta- opioid receptors, explaining their use by chronic narcotics users to ameliorate opioid withdrawal symptoms. Despite their widespread Internet availability, use of Salvia divinorum and Kratom represents an emerging trend that escapes traditional methods of toxicologic monitoring. The purpose of this article is to familiarize toxicologists and poison control specialists with these emerging psychoactive dietary supplements.

Acknowledgments

The authors gratefully acknowledge the contribution of Fire Erowid and Earth Erowid of www.erowid.org, and Drs. Melisa W. Lai and Robert S. Hoffman to the generation of this article. Dr. Boyer is supported by NIH grant R21 DA14929.

Notes

8. Herbal Smoke and Legal Bud Shop. (http://iamshamanshop.com/). (2 Januaey 2007).

17. “Salvia divinorum/ Maria Pastora” keyword search for 2000–2005. American Association of Poison Control Centers database. Conducted April 26, 2006.

36. “Mitragyna speciosa” keyword search for 2000–2005. American Association of Poison Control Centers database. Conducted April 26, 2006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.